主动脉分叉覆膜支架重建技术治疗主髂动脉闭塞病的3年结果
本研究回顾性分析两个中心2009年2月至2016年7月接受CERAB技术治疗的130例主髂动脉闭塞病患者,随访中位24个月,评估3年通畅率与临床改善。结果显示技术成功率97%,1年与3年临床改善率分别为94%和96%,3年一期、一期辅助及二期通畅率分别为82%、87%和97%,免于临床驱动的靶病变血运重建率为86%。CERAB技术安全可行,3年通畅与临床改善良好。
要点
- CERAB技术治疗广泛AIOD技术成功率97%,67%完全经皮完成。
- 3年一期、一期辅助、二期通畅率分别为82%、87%、97%。
- 1年与3年免于临床驱动靶病变血运重建率分别为87%和86%。
核心结论
- CERAB技术治疗广泛主髂动脉闭塞病安全可行,3年通畅率与临床改善结果良好。
研究设计与样本
- 回顾性分析两个中心2009年2月至2016年7月接受CERAB技术治疗的130例AIOD患者(69男61女)。
- 随访包括临床评估、双功超声和踝肱指数,采用Kaplan-Meier分析通畅率和临床驱动靶病变血运重建。
主要发现
- 68%患者为间歇性跛行,32%为严重肢体缺血;89%为TASC II D级病变,B级和C级各5%。
- 中位随访24个月(范围0-67个月),技术成功率97%,67%病例完全经皮完成。
- 踝肱指数从术前0.65±0.22显著改善至术后0.88±0.15。
- 30天轻微和严重并发症发生率分别为33%和7%,中位住院时间2天(范围1-76天)。
- 1年和3年分别有94%和96%患者临床改善至少一个Rutherford分级(未改善2%和0%,恶化4%和4%);1年和3年保肢率分别为98%和97%。
关键数值与推荐
- 1年、2年、3年一期通畅率分别为86%、84%、82%。
- 1年、2年、3年一期辅助通畅率分别为91%、89%、87%。
- 1年、2年、3年二期通畅率均为97%。
- 1年免于临床驱动靶病变血运重建率为87%,2年和3年均为86%。
临床怎么用
- CERAB技术可作为广泛AIOD的治疗选择,尤其适用于TASC II D级病变。
- 术后需规律随访评估通畅率及临床驱动靶病变血运重建。
局限性
- 回顾性研究,仅纳入两个中心数据。
- 中位随访24个月,部分患者随访不足3年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to demonstrate the 3-year outcome of the covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for the treatment of extensive aortoiliac occlusive disease (AIOD). METHODS: Between February 2009 and July 2016, all patients treated with the CERAB technique for AIOD were identified in the local databases of two centers and analyzed. Demographics and lesion characteristics were scored. Follow-up consisted of clinical assessment, duplex ultrasound, and ankle-brachial indices. Patency rates and clinically driven target lesion revascularization were calculated by Kaplan-Meier analysis. RESULTS: Of 130 patients (69 male and 61 female) treated, 68% were diagnosed with intermittent claudication and 32% suffered from critical limb ischemia. The majority (89%) were TransAtlantic Inter-Society Consensus II D lesions, and the remaining were B and C lesions (both 5%). Median follow-up was 24 months (range, 0-67 months). The technical success rate was 97%, and 67% of cases were performed completely percutaneously. The ankle-brachial index improved significantly from 0.65 ± 0.22 preoperatively to 0.88 ± 0.15 after the procedure. The 30-day minor and major complication rate was 33% and 7%. The median hospital stay was 2 days (range, 1-76 days). At 1 year and 3 years of follow-up, 94% and 96% of the patients clinically improved at least one Rutherford category (2% and 0% unchanged, 4% and 4% worsened). Limb salvage rate was 98% at 1 year and 97% at 3 years of follow-up. Primary, primary assisted, and secondary patency was 86%, 91%, and 97% at 1 year; 84%, 89%, and 97% at 2 years; and 82%, 87%, and 97% at 3 years. Freedom from clinically driven target lesion revascularization was 87% at 1-year follow-up and 86% at both 2-year and 3-year follow-up. CONCLUSIONS: The CERAB technique is a safe and feasible technique for the treatment of extensive AIOD with good 3-year results regarding patency and clinical improvement.
引用
- Taeymans K, Groot Jebbink E, Holewijn S, et al. Three-year outcome of the covered endovascular reconstruction of the aortic bifurcation technique for aortoiliac occlusive disease. J Vasc Surg. 2017. PMID: 29169878. doi:10.1016/j.jvs.2017.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。